Benitec Biopharma (BNTC) Equity Ratio (2019 - 2025)
Historic Equity Ratio for Benitec Biopharma (BNTC) over the last 7 years, with Q1 2025 value amounting to 3.02.
- Benitec Biopharma's Equity Ratio rose 29379.23% to 3.02 in Q1 2025 from the same period last year, while for Mar 2025 it was 3.02, marking a year-over-year increase of 29379.23%. This contributed to the annual value of 0.9 for FY2024, which is 189987.36% up from last year.
- Latest data reveals that Benitec Biopharma reported Equity Ratio of 3.02 as of Q1 2025, which was up 29379.23% from 3.56 recorded in Q4 2024.
- Benitec Biopharma's Equity Ratio's 5-year high stood at 3.56 during Q4 2024, with a 5-year trough of 0.05 in Q2 2023.
- Over the past 5 years, Benitec Biopharma's median Equity Ratio value was 0.81 (recorded in 2022), while the average stood at 1.03.
- In the last 5 years, Benitec Biopharma's Equity Ratio plummeted by 9062.17% in 2023 and then skyrocketed by 189987.36% in 2024.
- Benitec Biopharma's Equity Ratio (Quarter) stood at 0.77 in 2021, then dropped by 2.3% to 0.76 in 2022, then decreased by 4.1% to 0.72 in 2023, then surged by 391.41% to 3.56 in 2024, then fell by 15.19% to 3.02 in 2025.
- Its Equity Ratio was 3.02 in Q1 2025, compared to 3.56 in Q4 2024 and 0.93 in Q3 2024.